Sarecycline

Sarecycline (initially known as WC-3035) is a tetracycline-derived antibiotic.

Paratek Pharmaceuticals, Inc. licensed the US rights to sarecycline for the treatment of acne in the United States to Actavis, a subsidiary of Allergan, while retaining rights in the rest of the world.[1]

Allergan initiated a Phase 3 study in December 2014 evaluating the efficacy and safety of sarecycline tablets 1.5 mg/kg per day taken orally for 12 weeks versus placebo in the treatment of Acne Vulgaris.[2] Two phase 3 randomized, multi-center, double-blind, placebo-controlled studies evaluating the efficacy and safety of sarecycline in moderate to severe acne reported positive results on 27 March 2017.[3]

Notes

http://www.chemspider.com/Chemical-Structure.28540486.html

https://pubchem.ncbi.nlm.nih.gov/compound/71296095#section=Top

http://adisinsight.springer.com/drugs/800026591

References

  1. ↑ https://www.bloomberg.com/research/stocks/snapshot/snapshot_article.asp?ticker=N4CN:GR&txtsize=s
  2. ↑ https://clinicaltrials.gov/ct2/show/NCT02320149
  3. ↑ "Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". www.globenewswire.com. Retrieved 16 May 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.